The Food and Drug Administration announced a number of actions to strengthen and add clarity to its advisory-committee process. Following up on recommendations of the Institute of Medicine, the measures include proposed new guidance on advisory-committee voting, on disclosing information on conflicts of interest, and on security and appropriate conduct for participants at meetings.
One of FDAs strengths is that we routinely enlist the nations leading experts to give us public advice on complex medical and scientific issues, said Randall Lutter, the agencys deputy commissioner for policy. The new steps were taking further enhance the transparency and reliability of our advisory committee processes.
The FDA is also making improvements to add transparency to its advisory committee Web site.
Recently, the agency posted the names of outside experts appointed a new risk-communication advisory committee that will make recommendations to the FDA on how best to communicate the risks and benefits of FDA-regulated products.
So far this year, the FDA has convened 47 meetings of expert independent panels to advise the agency on topics such as new gene therapies and the safety of childrens cough and cold medicines, the agency stated. For more information, click here. -- by Jennifer Lubell
What do you think? Post a comment on this article and share your opinion with other readers. Submit your letter to Modern Healthcare Online at [email protected]. Please be sure to include your hometown and state, along with your organization and title.